EU-Commission Supplementary Statement of Objections | Merck global

01 Jul 2020 | Darmstadt, Germany

Merck today received a Supplementary Statement of Objections (SSO) from the European Commission (EU Commission) in the ongoing proceedings concerning the Sigma-Aldrich acquisition, which was completed in 2015. In July 2017, Merck received a Statement of Objections from the European Commission. This relates to a packaging technology developed by Sigma-Aldrich prior to its acquisition by Merck.

The SSO states that the allegations previously made against Merck will be dropped. The SSO retains allegations made against Sigma-Aldrich, which will be the object of the ongoing proceedings.

From the very beginning of the antitrust review proceeding, Merck has cooperated and engaged in a constructive dialogue with the European Commission.

Merck is confident that it will be possible to resolve the situation satisfactorily. Since this matter is still ongoing, Merck will not comment any further on it at this point in time.


More:  LYNPARZA® (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone

More from: | Category: Pharmaceutical Company News